Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-\(\alpha\)

Pierre Deltenre\(^a,b\), Christian Labenz\(^c\) and Marcus Schuchmann\(^d\)

Objective Quality of life (QoL) is impaired in patients with hepatic encephalopathy and rifaximin-\(\alpha\) can improve QoL within 6 months. This study assessed the importance of QoL as a therapeutic objective in hepatic encephalopathy management; whether QoL is routinely assessed in hepatic encephalopathy patients in clinical practice and the role of rifaximin-\(\alpha\) in this context.

Methods A survey was conducted of healthcare professionals (HCPs) from Europe and Australia involved in hepatic encephalopathy management. HCPs rated the importance of a range of therapeutic objectives on a 1–7 Likert scale (1 = not at all important; 7 = extremely important). HCPs were also required to provide three patient record forms (PRFs) based on their last three hepatic encephalopathy patients.

Results There were 218 HCP respondents, who provided 654 PRFs (patients treated with rifaximin-\(\alpha\), \(n=347\); patients not treated with rifaximin-\(\alpha\), \(n=307\)). The mean Likert score was highest for the therapeutic objective ‘improving a patient's QoL’ (6.4), which was rated significantly more highly than all other therapeutic objectives, including ‘reducing the patient’s likelihood of hospital readmission’ (6.1; \(P<0.001\)) and ‘preventing death of the patient’ (6.1; \(P<0.001\)). Despite this, only 28.3% of PRFs documented specific QoL data assessment. Patients receiving rifaximin-\(\alpha\) were treated later in their disease course than those not receiving rifaximin-\(\alpha\).

Conclusions HCPs consider QoL improvement the main therapeutic objective in hepatic encephalopathy management, but most do not explicitly assess QoL. Earlier introduction of rifaximin-\(\alpha\) may safeguard QoL improvement even when QoL monitoring is not possible. Eur J Gastroenterol Hepatol 33: e1032–e1038

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Introduction

Hepatic encephalopathy is a brain dysfunction caused by either liver insufficiency or portosystemic shunting or both, which manifests as a wide spectrum of neurologic or psychiatric abnormalities, ranging from subclinical alterations to coma [1]. Although the aetiology of hepatic encephalopathy has not been conclusively established, its pathophysiology is thought to involve elevated blood levels of gut-derived neurotoxins (particularly ammonia) entering the brain, due to the inability of the damaged liver to remove them from the blood circulation [2,3].

Systemic inflammation, neuroinflammation and endotoxaemia are also thought to be implicated [4]. Hepatic encephalopathy is one of the most debilitating complications of liver disease [1] and is associated with increased mortality [3,5]. Hepatic encephalopathy negatively affects patients’ quality of life (QoL), both physically and mentally [6], resulting in a substantial burden on the lives of both patients and caregivers [1,7]. The economic burden of hepatic encephalopathy is also profound [8,9].

Hepatic encephalopathy guidelines recommend both the active treatment of overt hepatic encephalopathy and secondary prophylaxis to prevent hepatic encephalopathy recurrence [1]. Lactulose is recommended as the first choice for acute treatment and for the prevention of recurrence [1]. Rifaximin is recommended as adjunctive therapy to lactulose for the prevention of overt hepatic encephalopathy recurrence after the second episode [1]. The guidelines also recommend that prophylactic therapy be continued, unless precipitating factors (e.g. variceal bleeding, infections) have been well controlled, or liver function or nutritional status have improved [1].

Rifaximin-\(\alpha\) is a locally acting oral antibiotic that is minimally absorbed in the gut to reduce the effects of intestinal flora, including ammonia-producing species [10–12]. It has also been shown to reduce the production of pro-inflammatory cytokines and endotoxin [4]. Rifaximin-\(\alpha\) is indicated in Europe, Australia and New Zealand for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients aged ≥18 years.
Evidence has demonstrated that the addition of rifaximin-α to standard lactulose therapy significantly reduces overt hepatic encephalopathy recurrence and hepatic encephalopathy-related hospitalisation, which may result in substantial reductions in healthcare resource utilisation over the long term [16–18]. Rifaximin-α has also been shown to significantly improve health-related QoL in patients with cirrhosis and recurrent hepatic encephalopathy [19].

Given the impact of hepatic encephalopathy on QoL, we conducted a survey of hepatic encephalopathy specialists in Europe and Australia to better understand how QoL is valued as an outcome measure in hepatic encephalopathy, whether QoL is routinely assessed in hepatic encephalopathy patients in clinical practice, and the role of rifaximin-α in this context.

**Methods**

**Study design**

Between September and December 2019, healthcare professionals (HCPs) from Australia, Belgium, Germany, Sweden, the Netherlands and the UK, with overall responsibility for the management of patients with hepatic encephalopathy, completed an online survey. These HCPs comprised hepatologists, gastroenterologists with special interest in hepatology and specialist liver nurses (UK only). In Germany, specialists included those who were hospital-based and office-based.

**Screening criteria**

To be included in the survey, HCPs were required to manage (i.e., diagnose, treat and discharge) patients with hepatic encephalopathy, and to be the main HCP for the long-term management of patients with hepatic encephalopathy at their institution. HCPs must personally have seen and treated at least 10 patients for hepatic encephalopathy (at least five patients in Belgium, Sweden, the Netherlands and Australia) in the last 3 months. HCPs were also required to have completed three patient record forms (PRFs) based on their last three patients with hepatic encephalopathy.

All patients recorded in PRFs were required to be aged between 18 and 75 years. PRFs of deceased patients or patients who were taking part in a clinical trial were excluded.

**Outcomes**

During the online survey, HCPs were asked the following questions: (1) ‘How important are each of the following therapy objectives to you for patients receiving hepatic encephalopathy primary or secondary prophylaxis therapy?’ and (2) ‘To what extent are each of the following factors important to you when deciding what therapies to prescribe to your patients for the prevention of further episodes of HE?’. The therapeutic objectives included in question 1 are outlined in Fig. 1a and the attributes included in question 2 are outlined in Fig. 1b. Responses were collected on a 1–7 Likert scale, where 1 corresponded to ‘not at all important’ and 7 corresponded to ‘extremely important’.

PRFs were assessed to determine a range of demographic, clinical and therapy-related information (Table 1). This included the documentation of information relating to QoL.

**Statistical methods**

All analyses were carried out using the statistical package R version 4.0.2 (The R Foundation for Statistical
Table 1. Summary of information documented in patient record forms

| Information                              | All patients | Patients who received rifaximin-α | Patients who did not receive rifaximin-α | P valuea |
|------------------------------------------|--------------|-----------------------------------|------------------------------------------|----------|
| Number of PRFs, N                        | 654          | 347                               | 307                                      |          |
| Country, n (%)                           |              |                                   |                                           |          |
| Australia                                |              | 68 (19.6)                         | 25 (8.1)                                 | <0.001   |
| Belgium                                  |              | 27 (7.8)                          | 33 (10.7)                                | 0.19     |
| Germany                                  |              | 92 (26.5)                         | 139 (45.3)                               | <0.001   |
| Netherlands                               |              | 10.5 (31.0)                       | 25 (8.1)                                 | 0.391    |
| Sweden                                   |              | 42 (12.1)                         | 18 (5.9)                                 | 0.006    |
| UK                                       |              | 83 (23.9)                         | 67 (21.8)                                | 0.525    |
| Age, mean (95% CI)                       |              | 57.5                               | 56.6 (55.4–56.7)                         | 0.033    |
| Male sex, n (%)                          |              | 451 (69.4)                        | 245 (71.0)                               | 0.338    |
| What was the precipitating factor for the patient’s last hepatic encephalopathy event? n (%) |              |                                   |                                           |          |
| Electrolyte or metabolic disturbance     |              | 181 (27.7)                        | 101 (29.1)                               | 0.385    |
| Drugs and medications                   |              | 73 (11.2)                         | 40 (11.5)                                | 0.753    |
| Infection                                |              | 196 (30.0)                        | 111 (32.0)                               | 0.231    |
| Constipation                             |              | 124 (19.0)                        | 65 (18.7)                                | 0.874    |
| Renal failure                            |              | 50 (7.6)                          | 26 (7.5)                                 | 0.876    |
| Variceal bleeding                        |              | 136 (20.8)                        | 69 (19.9)                                | 0.543    |
| Ascites                                  |              | 139 (21.3)                        | 78 (22.5)                                | 0.417    |
| Transjugular intrahepatic portosystemic shunt |          | 36 (5.5)                          | 22 (6.3)                                 | 0.32     |
| Other                                    |              | 28 (4.3)                          | 16 (4.6)                                 | 0.659    |
| Unknown                                  |              | 51 (7.8)                          | 21 (6.1)                                 | 0.077    |
| Who referred the patient to you? n (%)   |              |                                   |                                           |          |
| Accident and emergency/emergency department/emergency room |              | 288 (44.0)                        | 163 (47.0)                               | 0.108    |
| Gastroenterology ward                    |              | 149 (22.8)                        | 86 (24.8)                                | 0.195    |
| Critical care                            |              | 31 (4.7)                          | 17 (4.9)                                 | 0.839    |
| Cardiology                               |              | 10 (1.5)                          | 2 (0.6)                                  | 0.035    |
| Nephrology                               |              | 7 (1.1)                           | 2 (0.6)                                  | 0.192    |
| Neurology                                |              | 3 (0.5)                           | 0                                        | 0.065    |
| Occupational therapy                     |              | 1 (0.2)                           | 1 (0.3)                                  | 0.347    |
| Rheumatology                             |              | 1 (0.2)                           | 0                                        | 0.288    |
| General medicine                         |              | 60 (9.2)                          | 29 (8.4)                                 | 0.442    |
| Primary care (general practitioner/primary care provider) |          | 83 (12.7)                         | 42 (12.1)                                | 0.632    |
| Geriatrics/care of the elderly           |              | 3 (0.5)                           | 3 (0.9)                                  | 0.103    |
| Psychiatry or addiction services         |              | 4 (0.6)                           | 1 (0.3)                                  | 0.26     |
| Office-based specialist (e.g., gastroenterologist) |          | 5 (0.8)                           | 2 (0.6)                                  | 0.558    |
| Other                                    |              | 6 (0.9)                           | 4 (1.2)                                  | 0.503    |
| Patient not referred                     |              | 49 (7.5)                          | 14 (4.0)                                 | <0.001   |
| What was the patient referred to you with? |              |                                   |                                           |          |
| Hepatic encephalopathy                   |              | 396 (60.6)                        | 229 (66.0)                               | 0.004    |
| Liver disease/cirrhosis of the liver     |              | 445 (68.0)                        | 253 (72.9)                               | 0.004    |
| Infection                                |              | 154 (23.5)                        | 89 (25.6)                                | 0.179    |
| Constipation                             |              | 76 (11.6)                         | 42 (12.1)                                | 0.683    |
| Renal failure                            |              | 65 (9.9)                          | 37 (10.7)                                | 0.511    |
| Variceal bleeding                        |              | 116 (17.7)                        | 55 (15.9)                                | 0.18     |
| Ascites                                  |              | 172 (26.3)                        | 99 (28.5)                                | 0.169    |
| Dementia                                 |              | 17 (2.6)                          | 8 (2.3)                                  | 0.616    |
| Stroke                                   |              | 21 (3.2)                          | 10 (2.9)                                 | 0.612    |
| Aphasias                                 |              | 6 (0.9)                           | 3 (0.9)                                  | 0.88     |
| Hepatitis                                |              | 57 (8.7)                          | 36 (10.4)                                | 0.11     |
| Other                                    |              | 13 (2.0)                          | 6 (1.7)                                  | 0.615    |
| What is the underlying cause of this patient’s liver disease? |              |                                   |                                           |          |
| Alcoholism                               |              | 440 (67.3)                        | 220 (63.4)                               | 0.025    |
| Hepatitis B                              |              | 56 (8.6)                          | 27 (7.8)                                 | 0.94     |
| Hepatitis C                              |              | 95 (14.5)                         | 55 (15.9)                                | 0.308    |
| Nonalcoholic fatty liver/nonalcoholic steatohepatitis |          | 103 (15.7)                        | 63 (18.2)                                | 0.073    |
| Acute liver failure (due to drug overdose) |          | 15 (2.3)                          | 11 (3.2)                                 | 0.112    |
| Acute liver failure (other cause)        |              | 20 (3.1)                          | 12 (3.5)                                 | 0.528    |
| Autoimmune hepatitis                     |              | 23 (3.5)                          | 11 (3.2)                                 | 0.609    |
| Autoimmune primary biliary cirrhosis     |              | 15 (2.3)                          | 10 (2.9)                                 | 0.286    |
| Autoimmune primary sclerosing cholangitis|              | 6 (0.9)                           | 5 (1.4)                                  | 0.136    |
| Other                                    |              | 16 (2.4)                          | 7 (2.0)                                  | 0.451    |
| Number of hepatic encephalopathy episodes the patient has had in the last 12 months, mean (95% CI) |          | 1.6 (1.4–1.7)                     | 1.7 (1.5–1.9)                           | 1.4 (1.2–1.6) | 0.032 |
| Number of hepatic encephalopathy episodes the patient has had since diagnosis, mean (95% CI) |              | 2.7 (2.5–2.9)                     | 3.1 (2.8–3.4)                          | 2.1 (1.9–2.3) | <0.001 |
| Which of the following comorbidities has the patient suffered from in the last 12 months? n (%) |              |                                   |                                           |          |
| Spontaneous bacterial peritonitis         |              | 164 (25.1)                        | 105 (30.3)                               | 0.001    |
| Renal failure                            |              | 134 (20.5)                        | 93 (26.8)                                | 0.001    |
| Variceal bleeding                        |              | 167 (25.5)                        | 96 (27.7)                                | 0.185    |
| Diabetes                                 |              | 129 (19.7)                        | 73 (21.0)                                | 0.371    |
| Obesity                                  |              | 150 (22.9)                        | 82 (23.6)                                | 0.654    |
| Cardiovascular disease                   |              | 99 (15.1)                         | 45 (13.0)                                | 0.1      |
| Inflammatory bowel disease               |              | 35 (5.4)                          | 15 (4.3)                                 | 0.214    |

(continued)
Table 1. (continued)

| Question                                                                 | All patients | Patients who received rifaximin-α | Patients who did not receive rifaximin-α | P valuea |
|--------------------------------------------------------------------------|--------------|----------------------------------|----------------------------------------|----------|
| Connective tissue disease                                                | 3 (0.5)      | 2 (0.6)                          | 1 (0.3)                                | 0.637    |
| Substance abuse (incl. alcohol and recreational drugs)                  | 177 (27.1)   | 84 (24.2)                        | 93 (30.3)                              | 0.081    |
| Other                                                                    | 32 (4.9)     | 18 (5.2)                         | 14 (4.6)                               | 0.711    |
| None                                                                     | 96 (14.7)    | 47 (13.5)                        | 49 (16.0)                              | 0.384    |
| Is the patient currently receiving therapy for hepatic encephalopathy prophylaxis? (Yes), n (%) | 553 (84.6)   | 327 (94.2)                       | 226 (73.6)                             | <0.001   |
| What is/are the current/most recent therapy/therapies the patient has received to reduce hepatic encephalopathy occurrence? n (%) |                          |                                  |                                       |          |
| Lactulose                                                                | 540 (82.6)   | 277 (79.8)                       | 263 (85.7)                             | 0.05     |
| Neomycin (UK: Nivemycin)                                                 | 28 (4.3)     | 10 (2.9)                         | 18 (5.9)                               | 0.06     |
| Rifaximin-α                                                              | 347 (53.1)   | 347 (100)                        | 0                                      | 1.000    |
| Metronidazole (UK: Flagyl)                                               | 38 (5.8)     | 15 (4.3)                         | 23 (7.5)                               | 0.084    |
| Probiotics                                                               | 67 (10.2)    | 26 (7.5)                         | 41 (13.4)                              | 0.014    |
| Saline enema                                                             | 30 (4.6)     | 15 (4.3)                         | 15 (4.9)                               | 0.732    |
| Other antibiotics                                                        | 15 (2.3)     | 6 (1.7)                          | 9 (2.9)                                | 0.306    |
| Other treatments                                                         | 13 (2.0)     | 9 (2.6)                          | 4 (1.3)                                | 0.239    |
| None                                                                     | 27 (4.1)     | 0                                | 27 (8.8)                               | <0.001   |
| Did you collect any QoL data for this patient?                           | 544 (83.2)   | 294 (84.7)                       | 250 (81.4)                             | 0.262    |
| Was a GP referral letter given to the patient when he or she was discharged from hospital? n (%) | 185 (28.3)   | 86 (24.8)                        | 99 (32.2)                              | 0.034    |
| L-ornithine-l-aspartate (Hepa-Merz) use (yes), n (%)                     | 77 (11.8)    | 29 (8.4)                         | 48 (15.6)                              | 0.004    |
| Duration since first diagnosis of hepatic encephalopathy, mean (95% CI) years | 2.9 (2.6–3.2)a | 2.9 (2.5–3.2)a | 3.0 (2.6–3.4)b | 0.696    |

CI, confidence interval; PRF, patient record form; QoL, quality of life.

*aP values for two sample t-tests comparing patients who received rifaximin-α vs. those who did not receive rifaximin-α.

Computing, 2020). Mean [95% confidence interval (CI)] Likert scores were calculated for the two survey questions. Two-sided t-tests were conducted to compare (1) the mean score for the therapeutic objective ‘improving a patient’s QoL’ with the mean scores for each of the other therapeutic objectives (question 1) and (2) the mean score for the attribute ‘patient’s QoL’ with the mean scores for each of the other attributes (question 2). Data from PRFs were assessed for the total patient population and for the subgroups of patients who received rifaximin-α (in any combination with other treatments) and those who did not receive rifaximin-α. Two sample t-tests were conducted to compare PRF characteristics between the subgroups of patients who were vs. were not treated with rifaximin-α.

**Ethics**

This survey study was conducted by Ipsos Healthcare, an independent market research agency based in Germany, on behalf of Norgine Ltd. The methodology complied with German Market Research Guidelines, European Society for Opinion and Market Research e.V. guidelines, the Working Group of German Market and Social Research (ADM) guidelines, and European Pharmaceutical Market Research Association (EphMRA) guidelines. As per EphMRA code of conduct 2019, section 1.3, this study complied with the European Federation of Pharmaceutical Industries and Associations requirements for market research (as opposed to clinical research), and thus did not require clinical research ethics committee approval. The study complied with all German data protection regulations. Participation in the online survey was voluntary. All patient data included in the PRFs were anonymised prior to assessment.

**Results**

**Study sample**

A total of 2996 HCPs were initially approached, from whom there were 218 respondents (Australia, n = 31; Belgium, n = 20; Germany, n = 77; Netherlands, n = 20; Sweden, n = 20 and UK, n = 50). HCPs provided a total of 654 PRFs (Australia, n = 93; Belgium, n = 60; Germany, n = 231; Netherlands, n = 60; Sweden, n = 60; UK, n = 150), comprising 347 patients treated with rifaximin-α and 307 patients not treated with rifaximin-α (Table 1).

**Online survey**

In answer to the question ‘How important are each of the following therapy objectives to you for patients receiving hepatic encephalopathy primary or secondary prophylaxis therapy?’ the mean Likert score was highest for ‘improving a patient’s quality of life’ (6.4) (Fig. 1a). The mean score for this therapeutic objective was significantly higher than the mean scores for all other therapeutic objectives, including ‘reducing the patients likelihood of hospital readmission’
(6.1; \(P<0.001\)) and ‘Preventing death of the patient’ (6.1; \(P<0.001\)). Mean scores for the therapeutic objective ‘improving a patient’s QoL’ ranged from 6.3 in Germany, the Netherlands and UK to 6.8 in Australia (Fig. 2).

In answer to the question ‘To what extent are each of the following factors important to you when deciding what therapies to prescribe to your patients for the prevention of further episodes of hepatic encephalopathy?’, the mean Likert score was highest for ‘improving a patient’s QoL’ (6.2) (Fig. 1b). The mean score for this attribute was significantly higher than the mean scores for all other attributes, with the exception of ‘efficacy in improving hepatic encephalopathy symptoms’ (6.1; \(P=0.525\)).

**Patient record forms**

Information documented in the PRFs is summarised in Table 1. The majority of patients in the overall sample were male (69.4%) and had been referred to their HCPs for liver disease/cirrhosis of the liver (68.0%) and/or hepatic encephalopathy (60.6%). Patients had experienced a range of comorbidities (complications of cirrhosis and other medical conditions) in the previous 12 months, including substance abuse (27.1%), variceal bleeding (25.5%), spontaneous bacterial peritonitis (25.1%), obesity (22.9%) and renal failure (20.5%).

Despite the high importance HCPs placed on QoL improvement, the proportion of patients who had QoL data documented was significantly lower than the proportion of patients who did not have QoL data documented (28.3 vs. 71.7%; \(P<0.001\)). The proportion of patients for whom QoL data were documented ranged from 2.2% in Australia to 51.7% in Belgium (Fig. 2).

Overall, while 84.6% (553/654) of patients were receiving some therapy for hepatic encephalopathy prophylaxis, 88.0% (227/258) of patients treated for secondary hepatic encephalopathy prophylaxis were treated with rifaximin-\(\alpha\). Patients treated with rifaximin-\(\alpha\) had experienced more hepatic encephalopathy episodes than those who did not receive rifaximin-\(\alpha\), both in the previous 12 months (mean 1.7 vs. 1.4; \(P=0.032\)) and since hepatic encephalopathy diagnosis (3.1 vs. 2.1; \(P<0.001\)). The proportions of patients with comorbidities commonly associated with hepatic encephalopathy was higher for patients receiving rifaximin-\(\alpha\) vs. those not receiving rifaximin-\(\alpha\): significantly higher for spontaneous bacterial peritonitis (30.3 vs. 19.2%; \(P=0.001\)) and numerically higher for variceal bleeding (27.7 vs. 23.1%; \(p=0.185\)). The proportion of patients with renal failure was also significantly higher for patients receiving rifaximin-\(\alpha\) vs. those not receiving rifaximin-\(\alpha\) (26.8 vs. 13.4%; \(P<0.001\)). The proportion of patients for whom QoL data were documented was significantly lower for those receiving rifaximin-\(\alpha\) vs. those not receiving rifaximin-\(\alpha\) (24.8 vs. 32.2%; \(P=0.034\)).

**Discussion**

This study revealed important insights into the therapeutic objectives of HCPs directly involved in the management of patients with hepatic encephalopathy. QoL emerged as the most important therapeutic objective overall, with a mean score of 6.4 on a Likert scale of 1–7 (where 7 corresponded to ‘extremely important’). Improving a patient’s QoL was rated significantly more highly than any other therapeutic objective, including reducing the likelihood of hospital readmission and preventing the death of the patient. Similarly, when HCPs were asked about factors that are important to them when deciding what therapies to prescribe patients to prevent further episodes of hepatic encephalopathy using PRFs.

![Fig. 2. Mean Likert scores for HCPs answering the survey question ‘How important are each of the following therapy objectives to you for patients receiving HE primary or secondary prophylaxis therapy? Improving a patient’s QoL’ and percentages of PRF forms that documented QoL data, by country. HCP, healthcare professional; PRF, patient record form; QoL, quality of life.](image-url)
Quality of life in hepatic encephalopathy

Deltenre et al.

Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

encephalopathy, QoL was again the most highly rated attribute, with a mean score of 6.2. QoL was rated significantly more highly than all the other attributes, with the exception of ‘efficacy in improving hepatic encephalopathy symptoms’, for which the mean score was still lower than that for QoL (6.1) but not significantly so.

There was a marked mismatch in the perceived importance of QoL as a therapeutic objective in hepatic encephalopathy management and the documented formal assessment of QoL in clinical practice, as demonstrated by the finding that only 28.3% of PRFs included QoL data. This mismatch was more notable in some countries than others; for example, HCPs from Australia gave QoL the highest rating of importance of all the countries included (mean score, 6.8), but only 2.2% of PRFs from Australia documented QoL data. Reasons for this mismatch are unclear but might include insufficient time in the clinic to assess QoL correctly, and a lack of easy-to-use measures to assess QoL in patients with hepatic encephalopathy. Tests validated for use in covert hepatic encephalopathy may prove useful in this regard; for example, the Clinical Covert Hepatic Encephalopathy score has been developed and validated for use as an easy-to-perform measure for identifying patients with cirrhosis at risk of covert hepatic encephalopathy, which has been shown to correlate with QoL and the risk of first-time overt hepatic encephalopathy [20]. Similarly, the Sickness Impact Profile questionnaire for Covert Hepatic Encephalopathy score is based on QoL outcomes and has been developed and validated as a simple, patient-administered, diagnostic measure to identify patients at high risk of developing overt hepatic encephalopathy who might benefit from prophylactic therapy [21]. Another explanation for this unexpected low rate of formal assessment of QoL in clinical practice may be related to a lack of precision of the question related to this item. In clinical practice, we can assume that some indicators of QoL, such as sleep disturbances or inversion of the circadian rhythm, are often (if not always) assessed when a patient with hepatic encephalopathy is seen. Overall, these data indicate that easy-to-use tools to assess QoL would be of interest and could help patient management.

The study also revealed further insights into the use of rifaximin-α. Among the 88.0% of patients who were treated for secondary hepatic encephalopathy prophylaxis with rifaximin-α, the vast majority 84.1% (191/227) also received lactulose, indicating a high acceptance of the concept of adding rifaximin-α to lactulose in this setting. This percentage is considerably higher than previous reports; for example, a retrospective analysis of a nationally representative US commercial claims database found that only 27.4% of patients with hepatic encephalopathy were prescribed rifaximin-α after being seen by gastroenterologist/hepatologist and advanced practice provider [22]. Similarly, an analysis of prescription patterns of general practitioners in Germany found that only 22.5% of patients were prescribed rifaximin-α after an episode of hepatic encephalopathy (Labenz, personal communication of unpublished data). Reasons for this discrepancy are unclear, but might indicate a level of recall bias in the current study. Patients who received rifaximin-α had experienced more hepatic encephalopathy episodes (in the previous 12 months and since hepatic encephalopathy diagnosis) than those who did not receive rifaximin-α. Patients treated with rifaximin-α also reported higher levels of comorbidities, such as spontaneous bacterial peritonitis, variceal bleeding and renal failure, than those not treated with rifaximin-α. These findings confirm that rifaximin-α is used relatively late in a patient’s disease course, most likely when lactulose alone is providing inadequate efficacy and/or the patient’s condition has worsened. Other potential reasons for the relatively late use of rifaximin-α may include local/national limitations and restrictions in the criteria for using rifaximin-α and institutional limitations in funding for rifaximin-α; although evidence has shown that the addition of rifaximin-α to lactulose therapy results in substantial reductions in healthcare resource utilisation over the long term [16–18].

Evidence demonstrates that patients treated with rifaximin-α relatively early in their disease course (during the first 6 months) experience improvements in QoL [19,23,24]. For example, a subanalysis of the pivotal rifaximin-α Phase 3 trial demonstrated that rifaximin-α significantly improved health-related QoL [assessed using the Chronic Liver Disease Questionnaire (CLDQ)] over 6 months in patients with cirrhosis who had experienced at least two overt hepatic encephalopathy episodes within the previous 6 months [19]. Statistically significant and clinically important improvements in health-related QoL measures were observed with rifaximin-α vs. placebo across each of the six CLDQ domains (fatigue, abdominal symptoms, systemic symptoms, activity, emotional function and worry) and for the overall CLDQ score (all P<0.0001) [19]. Other evidence has shown that treatment of minimal hepatic encephalopathy with lactulose, probiotics or L-ornithine L-aspartate can improve health-related QoL [25–27], further supporting early intervention to improve QoL outcomes.

A limitation of this study was that QoL monitoring was assessed by examining the documentation of QoL information in PRFs, which may have underestimated the overall assessment of QoL by HCPs, because the content of conversations resulting from general enquiries that might have encompassed aspects of QoL, such as ‘How are you feeling?’, may not have been captured in PRFs. In addition, the reported high use of rifaximin-α for secondary hepatic encephalopathy prophylaxis, in comparison with other studies, may indicate a level of recall bias in the current study, as previously mentioned.

In conclusion, the findings from this study demonstrate that improvement in QoL is a top-rated outcome in hepatic encephalopathy management. However, it seemed to be rarely assessed in this study performed in European and Australian patients with hepatic encephalopathy. The earlier introduction of rifaximin-α may safeguard QoL improvement even when QoL monitoring is not easy to assess. Easy-to-use tools are needed to assess QoL in clinical practice in patients with hepatic encephalopathy.

Acknowledgements

Editorial support was provided by John Scopes of mXm Medical Communications and funded by Norgine. This study and manuscript preparation were funded by Norgine Ltd.
Conflicts of interest

P.D.: Previous honoraria from Norgine. C.L.: Previous publication honoraria from Norgine. Research grants from Merz and Norgine. M.S.: Speaker and consultant for AbbVie, Falk, Gilead, Intercept and Norgine.

References

1. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol 2014; 61:642–659.

2. Williams R. Review article: bacterial flora and pathogenesis in hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25(Suppl 1):17–22.

3. Elwir S, Rahimi RS. Hepatic encephalopathy: an update on the pathophysiology and therapeutic options. J Clin Transl Hepatol 2017; 5:142–151.

4. Luo M, Guo JY, Cao WK. Inflammation: a novel target of current therapies. Gut Microbes 2014; 5:82–89.

5. Cordoba J, Ventura-Cots M, Simón-Talero M, Amorís A, Pavesi M, Villstrup H, et al; CANONIC Study Investigators of EASL-CILF Consortium. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol 2014; 60:275–281.

6. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48:1622–1629.

7. Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 2011; 106:1646–1653.

8. Krag A, Schuchmann M, Sodatonou H, Pilot J, Whitehouse J, Strasser S, et al. Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients’ Experience on Rifaximin-a (PROSPER): an observational study among 550 patients. Hepatol Commun 2018; 3:4.

9. Patel D, McPhail MJ, Cobbold JF, Taylor-Robinson SD. Hepatic encephalopathy. Br J Hosp Med (Lond) 2012; 73:79–85.

10. Scott LJ. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes. Drugs 2014; 74:2153–2160.

11. Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther 2016; 43(Suppl 1):11–26.

12. Ponzianni FR, Gerard V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2018; 24:12322–12333.

13. TARGAXAN® Summary of Product Characteristics. Norgine Limited. [Online, 13 July 2021] https://www.medicines.org.uk/emc/medicines/27427. 2021.

14. XIFAXAN® New Zealand Datasheet. Norgine Pty Ltd. [Online, 13 July 2021] https://www.medsafe.govt.nz/profs/Datasheet/x/xifaxantab.pdf. 2017.

15. XIFAXAN® Australian Product Information. Norgine Pty Ltd. [Online, 13 July 2021] https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-Pi-02052-3&d=20210217101633. 2020.

16. Bass NM, Mullen KD, Sanyal A, Poodrad F, Neff G, Levey CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071–1081.

17. Mullen KD, Sanyal AJ, Bass NM, Poodrad FF, Sheikh MV, Frederick RT, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014; 12:1390–1397.e2.

18. Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol 2019; 31:434–450.

19. Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poodrad F, Brown RS, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011; 34:853–861.

20. Labenz C, Toenges G, Huber Y, Nagel M, Marquardt JU, Schattenberg JM, et al. Development and validation of a prognostic score to predict covert hepatic encephalopathy in patients with cirrhosis. Am J Gastroenterol 2019; 114:764–770.

21. Lauridsen MM, Jepsen P, Wernberg CW, Schaftlatszyk de Muckadell OB, Bajaj JS, et al. Validation of a simple quality-of-life score for identification of minimal and prediction of overt hepatic encephalopathy. Hepatol Commun 2020; 4:1353–1361.

22. Tapper EB, Hao S, Lin M, Mafi JN, McCurdy H, Parkh ND, et al. The quality and outcomes of care provided to patients with cirrhosis by advanced practice providers. Hepatology 2020; 71:225–234.

23. Suzuki K, Endo R, Takikawa Y, Moriyasu F, Aoyagi Y, Moriwaki H, et al. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: a phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res 2018; 48:411–423.

24. Bruyneel M, Sersita T, Libert W, van den Broecke S, Ameye L, Dachy B, et al. Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin. Eur J Gastroenterol Hepatol 2017; 29:302–308.

25. Mittal V, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2011; 23:725–732.

26. Luo M, Li L, Lu CZ, Cao WK. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2011; 23:1250–1257.

27. Wang YJ, Bajaj JS, Wang JB, Shang J, Zhou XM, Guo XL, et al. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial. J Dig Dis 2019; 20:547–556.

Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.